134 related articles for article (PubMed ID: 34469571)
21. Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra).
Koné-Paut I; Retornaz K; Garnier JM; Bader-Meunier B
Clin Exp Rheumatol; 2007; 25(1):119. PubMed ID: 17418007
[No Abstract] [Full Text] [Related]
22. [Anakinra treatment in refractory systemic onset juvenile arthritis].
Garrido Colino C; Saavedra Lozano J
An Pediatr (Barc); 2008 Mar; 68(3):305-6. PubMed ID: 18358148
[No Abstract] [Full Text] [Related]
23. Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.
Ter Haar NM; Tak T; Mokry M; Scholman RC; Meerding JM; de Jager W; Verwoerd A; Foell D; Vogl T; Roth J; Leliefeld PHC; van Loosdregt J; Koenderman L; Vastert SJ; de Roock S
Arthritis Rheumatol; 2018 Jun; 70(6):943-956. PubMed ID: 29426067
[TBL] [Abstract][Full Text] [Related]
24. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
25. Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry.
Giancane G; Papa R; Vastert S; Bagnasco F; Swart JF; Quartier P; Antón J; Kamphuis S; Sanner H; Glerup M; De Benedetti F; Tsitsami E; Remesal A; Moreno E; De Inocencio J; Myrup C; Pallotti C; Koné-Paut I; Franck-Larsson K; Malmström H; Cederholm S; Pistorio A; Wulffraat N; Ruperto N;
J Rheumatol; 2022 Apr; 49(4):398-407. PubMed ID: 35105709
[TBL] [Abstract][Full Text] [Related]
26. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.
Kahn PJ; Cron RQ
J Rheumatol; 2013 May; 40(5):743-4. PubMed ID: 23637382
[No Abstract] [Full Text] [Related]
27. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
[TBL] [Abstract][Full Text] [Related]
29. Severe Immediate and Delayed Hypersensitivity Reactions to Biologics in a Toddler With Systemic Juvenile Idiopathic Arthritis.
Villacis-Nunez DS; Bilcha K; Spraker M; Rouster-Stevens K; Cooley A
J Investig Med High Impact Case Rep; 2022; 10():23247096221077836. PubMed ID: 35225032
[TBL] [Abstract][Full Text] [Related]
30. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
31. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
33. Anakinra for macrophage activation syndrome.
Patoulias D
Eur J Intern Med; 2023 May; 111():133-134. PubMed ID: 36610874
[No Abstract] [Full Text] [Related]
34. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
[TBL] [Abstract][Full Text] [Related]
35. Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome - Successful use of PET- CT and Anakinra in its diagnosis and treatment.
Tayer-Shifman OE; Ben-Chetrit E
Mod Rheumatol; 2015; 25(6):954-7. PubMed ID: 24252009
[TBL] [Abstract][Full Text] [Related]
36. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
[TBL] [Abstract][Full Text] [Related]
38. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
[TBL] [Abstract][Full Text] [Related]
39. Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis.
Pardeo M; Rossi MN; Pires Marafon D; Sacco E; Bracaglia C; Passarelli C; Caiello I; Marucci G; Insalaco A; Perrone C; Tulone A; Prencipe G; De Benedetti F
Arthritis Rheumatol; 2021 Jun; 73(6):1053-1061. PubMed ID: 33615724
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
